Individual medical history, current medications, and specific health goals will play a role in tailoring the most effective plan for your needs
28, 2025, semaglutide (Ozempic) received FDA approval to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease) and death due to cardiovascular disease in adults with type 2 diabetes (T2DM) and chronic kidney disease (CKD)
[DOI] [PubMed] [Google Scholar] 38.Wang J., Chen S., Xu S., et al
FDA approval for its once-daily oral semaglutide (Wegovy) tablet, becoming the first oral GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight conditions
The key is matching the peptide to the right problem
Adipose tissue, especially visceral fat around the abdominal organs, is biologically active